Forteza SM, García SD, Pérez TM, Alert SJ, Reno CJ

Language: Spanish
References: 30
Page: 1-11
PDF size: 580.21 Kb.

ABSTRACT

Introduction: Cancer is the second main cause of infant mortality in the world. Children with cancer are treated with antineoplastic drugs and experience neutropenia as a direct result of the treatment.
Objective: To describe the presence of neutropenia as an adverse reaction of chemotherapy and the effectiveness of Hebervital in its prevention in patients treated in the service of Oncopediatrics at the National Institute of Oncology and Radiobiology.
Methods: A descriptive, cross-sectional and retrospective study was carried out from January 1st, 2006 to December 31st, 2016 according to demographic, clinical and therapeutic variables. Patients were identified from the hospital record´s databases on the service of Oncopediatrics of the National Institute of Oncology and Radiobiology. There were selected all patients with a diagnosis of secondary neutropenia induced by chemotherapy and who received treatment with Hebervital. The statistical analysis was carried out with the SPSS program 2 1.0 version.
Results: From the 512 patients with cancer treated in the service of Oncopediatrics, 369 presented neutropenia (72 %), most often grade II (35.3 %). There was a predominance of the age group of 0 to 5 years and main locations of the disease were: lymphomas and sarcomas. It was demonstrated a favourable response (80%) to granulocyte colonies stimulating factor in the grade IV neutropenia.
Conclusions: Neutropenia occurred in 67% of the cases treated with chemotherapy with a favourable response to the use of Hebervital according to the grade of neutropenia.

REFERENCES

1. Uribe C, Amado A, Ramírez G, Alarcón I. Cáncer infantil en el área metropolitana de Bucaramanga 2003-2007. MedUNAB. 2011;14(2):86-93.

2. González-Galvis MP, Sosa-Ávila LM, Rueda-Arenas E. Abordaje del paciente pediátrico con neutropenia febril y enfermedad oncológica. MÉD UIS. 2015;28(3):353- 62.

3. Lyman GH, Abella E, Pettengell R. Risk factors for febrile neutropenia among patients with cancer receiving chemotherapy: a systematic review. Crit Rev Oncol Hematol. 2014;90:190-199. DOI: 10.1016/j.critrevonc.2013.12.006

4. Der Simonian R, Laird N Meta-analysis in clinical trials revisited. Contemp Clin Trials 2015;45:139-145.

5. Phillips B, Wade R, Stewart LA, Sutton AJ. Systematic review and meta-analysis of the discriminatory performance of risk prediction rules in febrile neutropenic episodes in children and young people. Eur J Cancer. 2010;46(16):2950-64.

6. Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2015;33:3199-3212. DOI: 10.1200/JCO.2015.62.3488

7. Matloob M, Fadoo Z. Febrile neutropenia in pediatric cancer patients: Experience from a tertiary health care facility of Pakistan. Pediatr Infect Dis J. 2014;6(3):89-93.

8. Ministerio de Salud Pública. Anuario Estadístico de Salud. Dirección Nacional de Registros Médicos y Estadísticas de Salud. La Habana: 2015.

9. Barton C, Waugh L, Nielsen M, Paulus S. Febrile neutropenia in children treated for malignancy. J Infect 2015;71:S27-35.

10. Nahon S, Rastkhah M, Ben AM, Soumoudronga RF, Gasnereau I, Labourey JL. Zarzio®, biosimilar of filgrastim, in prophylaxis of chemotherapy-induced neutropenia in routine practice: a French prospective multicentric study. Support Care Cancer. 2016;24:1991-1998. DOI: 10.1007/s00520-015-2986-0

11. Tai E, Guy G, Dunbar A, Richardson L. Cost of cancer-related neutropenia or fever hospitalizations, United States, 2012. J Oncol Pract 2017;13(6):e552-e61

12. Link H, Nietsch J, Kerkmann M, Ortner P, Supportive Care Group of the German Cancer S Adherence to granulocyte-colony stimulating factor (G-CSF) guidelines to reduce the incidence of febrile neutropenia after chemotherapy--a representative sample survey in Germany. Support Care Cancer. 2016;24:367-376. DOI: 10.1007/s00520-015-2779-5

13. Comité Nacional de Infectología Pediátrica. Consenso sobre el cuidado del paciente oncológico neutropénico febril. Actualización 2008-2009. Arch Argent Pediatr. 2010;108(2)47-70.

14. Paganini H, Santolaya M, Álvarez M, Araña Rosaínz M, Arteaga Bonilla R, Bonilla A, y col. Diagnóstico y tratamiento de la neutropenia febril en niños con cáncer: Consenso de la Sociedad Latinoamericana de Infectología Pediátrica. Rev Chil Infect 2011;28:10-38.

15. Paganini H, Aguirre C, Puppa G, Garbini C, Javier R G, Ensinck G, et al. A prospective, multicentric screening system to predict mortality in febrile neutropenic children with cancer. Cancer 2007;109:2572-9.

16. NCCN Clinical Practice Guidelines in Oncology: Myeloid Growth Factors Version 1. 2016.

17. Canadian Agency for Drugs and Technologies in Health (CADTH): Common Drug Review – Subsequent Entry Biologic Review Report for Grastofil. 2016 [acceso 28/09/2017]. Disponible en: https://www.cadth.ca/sites/default/files/cdr/seb/SE0446_Grastofil_SEB_Report.pdf

18. Gascon P, Aapro M, Ludwig H, Bokemeyer C, Boccadoro M, Turner M, et al. Treatment patterns and outcomes in the prophylaxis of chemotherapy-induced (febrile) neutropenia with biosimilar filgrastim (the MONITOR-GCSF study) Support Care Cancer. 2016;24:911-925. DOI: 10.1007/s00520-015-2861-z

19. The National Comprehensive Cancer Network practice guidelines for myeloid growth factors v2.2018. [acceso 21/09/2018]. Disponible en https://www.nccn.org/professionals/physician_gls/pdf/myeloid_growth.pdf.

20. Blackwell K, Semiglazov V, Krasnozhon D, Davidenko I, Nelyubina L, Nakov R, et al. Comparison of EP2006, a filgrastim biosimilar, to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy. Ann Oncol. 2015;26:1948-1953. DOI: 10.1093/annonc/mdv281

21. Callenco-Serrano R, Gómez-Barreto D. Manejo del paciente neutropénico febril. Bol Med Hosp Infant Mex 2000;57:404-15.

22. Pettengell R, Schwenkglenks M, Bacon P, Lawrinson S, Duehrsen U. Pegfilgrastim primary prophylaxis in patients with non-Hodgkin lymphoma: results from an integrated analysis. Hematol Oncol. 2015;29(4):117-84.

23. Damaj GL, Benbrahim O, Hacini M, Voronina I, Benabed K, Soumoudronga RF, et al. ZOHé: A Prospective Study of the Use of Biosimilar Filgrastim Zarzio in Clinical Practice in Patients Treated with Chemotherapy for Lymphoid Malignancies. Clin Lymphoma Myeloma Leuk. 2017;17:362-9.e2. DOI: 10.1016/j.clml.2017.05.002

24. Sorgel F, Schwebig A, Holzmann J, Prasch S, Singh P, Kinzig M. Comparability of biosimilar filgrastim with originator filgrastim: protein characterization, pharmacodynamics, and pharmacokinetics. BioDrugs. 2015;29:123-131. DOI: 10.1007/s40259-015-0124-7

25. Schwartzberg LS, Lal LS, Balu S. Clinical Outcomes of Treatment with Filgrastim Versus a Filgrastim Biosimilar and Febrile Neutropenia-Associated Costs Among Patients with Nonmyeloid Cancer Undergoing Chemotherapy. J Manag Care Spec Pharm. 2018:1-9.

26. James E, Trautman H, Szabo E, Tang B. Budget impact analysis of switching chemotherapy patients using granulocyte colony-stimulating factors (G-CSFs) from pegfilgrastim to short-acting G-CSFs in the United States [Abstract 4668] American Society of Hematology; 2017.

27. Ramos Cedeño AM, Pérez Ruiz L, Fernández Ávila JD. Evaluación de la eficacia del Ior® LeukoCIM en pacientes con neutropenia. Medisur. 2007;5(3).

28. Mendoza Hernández I, Cachimaille Benavides Y, Guerra Chaviano PP, Robaina García M, Damaso Fernández J, Wilford de León M, y col. Impacto en la asistencia médica cubana de la extensión nacional del Ior® LeukoCIM a través de ensayos clínicos. La Habana: Centro Nacional Coordinador de Ensayos Clínicos. MEDISAN. 2013;17(1):45

29. Pérez R, Fernández A, Ramos C. Factor estimulante de colonias de granulocitos en el tratamiento ambulatorio de la neutropenia posterior a la quimioterapia. Revista panamericana de salud. Revista Panamericana de Salud Pública, 2009;26(3):281-282·

30. Zarzio® Summary of Product Characteristics. Sandoz, Holzkirchen, Germany. [acceso 28/10/2018]. Disponible en: https://www.ema.europa.eu/documents/productinformation/ zarzio-epar-product-information_en.pdf